Vutiglabridin

Research use only, not for human use.

Vutiglabridin (HSG4112) is a novel and safe modulator of PON2, a racemic compound. vutiglabridin is an optimized structural analogue of Glabridin and is superior to Glabridin in terms of weight loss and chemical stability.

Vutiglabridin (HSG4112), a racemic compound, is a potent anti-obesity agent. Vutiglabridin, an optimized structural analog of Glabridin, markedly supersedes Glabridin in weight reduction efficacy and chemical stability.

——

Vutiglabridin (HSG4112) fully reverses adiposity in HFD-induced obese mice in a dose-dependent manner. Vutiglabridin (orally administered with 10, 30, or 100?mg/kg dose for 6 weeks) dose-dependently reduces body weight and normalizes obesity-related parameters in high-fat diet (HFD)-induced obese mice.Animal Model:HFD-induced obese male C57BL/6J mice Dosage:10, 30, and 100?mg/kg Administration:Orally administered for 6 weeks Result:Led to significant dose-dependent body weight reduction by 4.0?g (8.3%), 10?g (21%), and 19?g (40%), respectively, compared to the 48.1?g body weight of HFD-induced obese mice administered with only the vehicle at 10, 30, and 100?mg/kg.

——

Metabolic Enzyme/Protease

Phosphatase

Phosphatase

——

——

1800188-47-9

354.44

C22H26O4

>98% (HPLC)

In Vitro:?DMSO : 100 mg/mL (282.14 mM; Ultrasonic )

CC1(C)OC2=C(C3=C(CC(CO3)C4=C(O)C=C(OCC)C=C4)C=C2)CC1

——

(-20℃)

With Ice Pack

≥ 2 years